Certain inhibitors of synthetic amyloid β-peptide (Aβ) fibrillogenesis block oligomerization of natural Aβ and thereby rescue long-term potentiation

Journal of Neuroscience

Volumn 25, Issue 10, 2005, Pages 2455-2462

  Walsh, Dominic M ^a,b,c   Townsend, Matthew ^a,b   Podlisny, Marcia B ^a,b   Shankar, Ganesh M ^a,b   Fadeeva, Julia V ^a,b   El Agnaf, Omar ^d   Hartley, Dean M ^a,b   Selkoe, Dennis J ^a,b,e  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY COLLEGE DUBLIN   (Ireland)

^d UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^e HARVARD INSTITUTES OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Amyloid peptide; Fibrillogenesis; LTP; Oligomers; Size exclusion chromatography

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN; MONOMER; OLIGOMER;

ALZHEIMER DISEASE; ARTICLE; FLUOROGRAPHY; GEL PERMEATION CHROMATOGRAPHY; IMMUNOPRECIPITATION; ISOTOPE LABELING; LONG TERM POTENTIATION; OLIGOMERIZATION; PRIORITY JOURNAL; WESTERN BLOTTING;

EID: 14944378094     PISSN: 02706474     EISSN: None     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.4391-04.2005     Document Type: Article

References (33)

1. Cohen FE, Kelly JW (2003) Therapeutic approaches to protein-misfolding diseases. Nature 426:905-909.
2. Davies CA, Mann DM, Sumpter PQ, Yates PO (1987) A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer's disease. J Neurol Sci 78:151-164.
3. Findeis MA (2002) Peptide inhibitors of beta amyloid aggregation. Curr Top Med Chem 2:417-423.
4. Haass C, Schlossmacher M, Hung AY, Vigo-Pelfrey C, Mellon A, Ostaszewski B, Lieberburg I, Koo EH, Schenk D, Teplow D, Selkoe D (1992) Amyloid β-peptide is produced by cultured cells during normal metabolism. Nature 359:322-325.
5. Hardy I, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297:353-356.
6. Hartley DM, Walsh DM, Ye CP, Diehl T, Vasquez S, Vassilev PM, Teplow DB, Selkoe DJ (1999) Protofibrillar intermediates of amyloid β-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J Neurosci 19:8876-8884.
7. Hsia AY, Masliah E, McConlogue L, Yu GQ, Tatsuno G, Hu K, Kholodenko D, Malenka RC, Nicoll RA, Mucke L (1999) Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci USA 96:3228-3233.
8. Ida N, Hartmann T, Pantel J, Schroder J, Zerfass R, Forstl H, Sandbrink R, Masters CL, Beyreuther K (1996) Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay. J Biol Chem 271:22908-22914.
9. Klein WL, Stine Jr WB, Teplow DB (2004) Small assemblies of unmodified amyloid beta-protein are the proximate neurotoxin in Alzheimer's disease. Neurobiol Aging 25:569-580.
10. Koo EH, Squazzo S (1994) Evidence that production and release of amyloid β-protein involves the endocytic pathway. J Biol Chem 269:17386-17389.
11. 1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 95:6448-6453.
12. Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE, Rogers J (1999) Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol 155:853-862.
13. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI, Masters CL (1999) Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 46:860-866.
14. Morishima-Kawashima M, Ihara Y (1998) The presence of amyloid β-protein in the detergent-insoluble membrane compartment of human neuroblastoma cells. Biochemistry 37:15247-15253.
15. Moyer Jr JR, Brown TH (1998) Methods for whole-cell recording from visually preselected neurons of perirhinal cortex in brain slices from young and aging rats. J Neurosci Methods 86:35-54.
16. Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L (2000) High-level neuronal expression of aβ1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci 20:4050-4058.
17. Nakagami Y, Nishimura S, Murasugi T, Kaneko I, Meguro M, Marumoto S, Kogen H, Koyama K, Oda T (2002a) A novel beta-sheet breaker, RS-0406, reverses amyloid beta-induced cytotoxicity and impairment of long-term potentiation in vitro. Br J Pharmacol 137:676-682.
18. Nakagami Y, Nishimura S, Murasugi T, Kubo T, Kaneko I, Meguro M, Marumoto S, Kogen H, Koyama K, Oda T (2002b) A novel compound RS-0466 reverses beta-amyloid-induced cytotoxicity through the Akt signaling pathway in vitro. Eur J Pharmacol 457:11-17.
19. Podlisny MB, Ostaszewski BL, Squazzo SL, Koo EH, Rydel RE, Teplow DB, Selkoe DJ (1995) Aggregation of secreted amyloid β-protein into SDS-stable oligomers in cell culture. J Biol Chem 270:9564-9570.
20. Rochet JC, Lansbury Jr PT (2000) Amyloid fibrillogenesis: themes and variations. Curr Opin Struct Biol 10:60-68.
21. Roher AE, Chaney MO, Kuo Y-M, Webster SD, Stine WB, Haverkamp LJ, Woods AS, Cotter RJ, Tuohy JM, Krafft GA, Bonnell BS, Emmerling MR (1996) Morphology and toxicityof Aβ-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease. J Biol Chem 271:20631-20635.
22. Selkoe DJ (2002) Alzheimer's disease is a synaptic failure. Science 298:789-791.
23. Stanton PK, Sarvey JM, Moskal JR (1987) Inhibition of the production and maintenance of long-term potentiation in rat hippocampal slices by a monoclonal antibody. Proc Natl Acad Sci USA 84:1684-1688.
24. Walsh DM, Lomakin A, Benedek GB, Maggio JE, Condron MM, Teplow DB (1997) Amyloid β-protein fibrillogenesis: detection of a protofibrillar intermediate. J Biol Chem 272:22364-22374.
25. Walsh DM, Hartley DM, Kusumoto Y, Fezoui Y, Condron MM, Lomakin A, Benedek GB, Selkoe DJ, Teplow DB (1999) Amyloid β-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. J Biol Chem 274:25945-25952.
26. Walsh DM, Tseng BP, Rydel RE, Podlisny MB, Selkoe DJ (2000) Detection of intracellular oligomers of amyloid β-protein in cells derived from human brain. Biochemistry 39:10831-10839.
27. Walsh DM, Klyubin I, Fadeeva J, William K, Cullen W, Anwyl R, Wolfe M, Rowan M, Selkoe D (2002a) Naturally secreted oligomers of the Alzheimer amyloid β-protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416:535-539.
28. Walsh DM, Klyubin I, Fadeeva JV, Rowan MJ, Selkoe DJ (2002b) Amyloid-β oligomers: their production, toxicity and therapeutic inhibition. Biochem Soc Trans 30:552-557.
29. Walsh DM, Hartley DM, Selkoe DJ (2003) The many faces of Aβ: structures and activity. Curr Med Chem Immunol Endocrinol Metab Agents 3:277-291.
30. Wang J, Dickson DW, Trojanowski JQ, Lee VM (1999) The levels of soluble versus insoluble brain Abeta distinguish Alzheimer's disease from normal and pathologic aging. Exp Neurol 158:328-337.
31. Wang Q, Walsh DM, Rowan MJ, Selkoe DJ, Anwyl R (2004) Block of long-term potentiation by naturally secreted and synthetic amyloid β-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5. J Neurosci 24:3370-3378.
32. Xia W, Zhang J, Kholodenko D, Citron M, Podlisny MB, Teplow DB, Haass C, Seubert P, Koo EH, Selkoe DJ (1997) Enhanced production and oligomerization of the 42-residue amyloid β-protein by Chinese hamster ovary cells stably expressing mutant presenilins. J Biol Chem 272:7977-7982.
33. Ye C, Walsh DM, Selkoe DJ, Hartley DM (2004) Amyloid β-protein induced electrophysiological changes are dependent on aggregation state: N-methyl-D-aspartate (NMDA) versus non-NMDA receptor/channel activation. Neurosci Lett 366:320-325.